Castle Biosciences Inc (CSTL): Total Liabilities
$107.68M
As of 2025-12-31
$91.15M
As of 2026-06-30
+30.7%
3-year compound annual growth
+35.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $107.68M | +42.8% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $75.40M | +21.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $62.07M | +28.8% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $48.18M | -5.2% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $50.83M | +115.1% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $23.64M | -31.8% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $34.63M | +6.6% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $32.48M | n/a | 2020-03-10, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $107.68M | +42.8% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $106.81M | +17.6% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $110.13M | -2.2% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $152.55M | +13.6% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $96.44M | -22.3% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $344.15M | -28.3% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $548.36M | -11.7% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $2.11B | +30.0% |
| Biodesix Inc (BDSX) | 2025-12-31 | $89.94M | +17.8% |
Compare CSTL, FLGT, CDNA, BLLN side by side · Screen every company in Services-Medical Laboratories ↗